Baseline characteristics
| All Patients | Bridge-to-TAVI/AVR | Destination | P value | |
| n=224 | n=136 | n=88 | ||
| Demographics: | ||||
| Age (years), mean ± SD | 82.5±8.3 | 82.8±7.4 | 82.0±9.5 | 0.51 |
| Male, n (%) | 117 (52.2) | 70 (51.5) | 47 (53.4) | 0.78 |
| BMI, mean ± SD* | 26.7±6.0 | 27.1±6.1 | 26.1±5.8 | 0.24 |
| Comorbidities: | ||||
| Hypertension, n (%) | 145 (64.7) | 90 (66.2) | 55 (62.5) | 0.57 |
| Hypercholesterolemia, n (%) | 122 (54.5) | 80 (58.8) | 42 (47.7) | 0.1 |
| Diabetes, n (%) | 68 (30.4) | 42 (30.9) | 26 (29.6) | 0.83 |
| Smoking history, n (%) | 97 (43.3) | 58 (42.7) | 39 (44.3) | 0.81 |
| COPD, n (%) | 45 (20.1) | 26 (19.1) | 19 (21.6) | 0.65 |
| Active malignancy, n (%) | 23 (10.3) | 11 (8.1) | 12 (13.6) | 0.18 |
| Atrial fibrillation, n (%) | 78 (34.8) | 42 (30.9) | 36 (40.9) | 0.12 |
| eGFR<30 | 32 (14.3) | 16 (11.8) | 16 (18.2) | 0.18 |
| Coronary artery disease, n (%) | 124 (55.4) | 74 (54.4) | 50 (56.8) | 0.72 |
| Prior MI, n (%) | 35 (15.6) | 17 (12.5) | 18 (20.5) | 0.11 |
| Prior PCI, n (%) | 27 (12.1) | 16 (11.8) | 11 (12.5) | 0.87 |
| Prior CABG, n (%) | 32 (14.3) | 20 (14.7) | 12 (13.6) | 0.82 |
| Prior BAV, n (%) | 22 (9.8) | 8 (5.9) | 14 (15.9) | 0.01 |
| Baseline Functional Status: | ||||
| Baseline NYHA score, mean ±SD | 2.9±0.7 | 2.9±0.7 | 3.0±0.8 | 0.24 |
| NYHA 1, n (%) | 7 (3.1) | 3 (2.2) | 4 (4.6) | 0.06 |
| NYHA 2, n (%) | 50 (22.3) | 32 (23.5) | 18 (20.5) | |
| NYHA 3, n (%) | 124 (55.4) | 82 (60.3) | 42 (47.7) | |
| NYHA 4, n (%) | 43 (19.2) | 19 (14.0) | 24 (27.3) | |
| Syncope, n (%) | 21 (9.4) | 17 (12.5) | 4 (4.6) | 0.05 |
| Cardiogenic shock, n (%) | 6 (2.7) | 0 (0) | 6 (6.8) | <0.01 |
| STS Risk Score, mean ±SD | 7.3±0.3 | 6.4±0.3 | 8.7±0.7 | <0.001 |
| Baseline Echocardiogram2: | ||||
| LVEF (%), mean ± SD | 47.7±16.9 | 50.3±15.3 | 43.6±18.5 | <0.01 |
| LVEF ≤40%, n (%) | 77 (35.2) | 40 (29.6) | 37 (44.1) | 0.03 |
| LVEDD (mm), mean ± SD | 49.1±8.4 | 48.7±7.8 | 49.9±9.5 | 0.34 |
| Aortic Valve: | ||||
| Aortic valve area (cm2), mean ± SD | 0.6±0.2 | 0.6±0.2 | 0.7±0.2 | 0.79 |
| Mean gradient (mmHg), mean ± SD | 46.1±19.0 | 47.5±19.8 | 43.8±17.4 | 0.16 |
| Low-gradient AS | 44 (20.4) | 22 (16.4) | 22 (26.8) | 0.07 |
| Mitral Regurgitation: | ||||
| None, n (%) | 48 (23.4) | 35 (28.0) | 13 (16.3) | 0.25 |
| Mild, n (%) | 93 (45.4) | 55 (44.0) | 38 (47.5) | |
| Moderate, n (%) | 58 (28.3) | 32 (25.6) | 26 (32.5) | |
| Severe, n (%) | 6 (2.9) | 3 (2.4) | 3 (3.8) | |
| E/e', mean ± SD | 23.0±11.5 | 20.5±8.9 | 27.0±14.0 | <0.001 |
*207 BMI measures available.
†219 TTE measures prior to BAV available.
AS, aortic stenosis; BAV, balloon aortic valvuloplasty; BMI, body mass index; CABG, coronary artery bypass grafts; COPD, chronic obstruction pulmonary disease; eGFR, estimated glomerular filtration rate; LVEDD, left ventricular end-diastolic diameter; LVEF, left ventricular ejection fraction; MI, myocardial infarction; NYHA, New York Heart Association; PCI, percutaneous coronary intervention; STS, Society of Thoracic Surgery.